Poster Presentation at AACR Annual Meeting

RNS Number : 7582H
Redx Pharma plc
15 March 2018
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx Pharma to present poster at prestigious American Association for Cancer Research Annual Meeting

 

Poster shows that lead candidate, RXC004 - a selective, orally bioavailable porcupine inhibitor- enhances immune response in pre-clinical models of cancer

 

Dosing recently commenced in phase 1/2a clinical trial of RXC004 in patients with hard to treat cancers

 

Alderley Park, March 15 2018 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the Company's submitted abstract has been accepted for presentation as a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, 14-18 April 2018.

 

The poster relates to the Company's lead candidate, RXC004, a potent and selective, orally bioavailable porcupine (PORCN) inhibitor, which is currently being investigated in a phase 1/2a clinical trial in patients with hard to treat cancers. It is expected that initial data from the 1a segment of this trial will be available in H2 2018.

 

Richard Armer, Chief Scientific Officer of Redx Pharma plc, commented, "We are delighted that our abstract has been accepted at such a high profile conference. We are excited by the potential of RXC004 as a treatment for challenging cancers and look forward to announcing the first data from our clinical development programme with this compound."

 

The abstract will be presented as a poster on 17 April 2018 8.00am - 12.00pm CST, further details below:

 

Session Category: Immunology

Session Title: Immunomodulatory Agents and Interventions 1

Abstract Title: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number: 14

Permanent Abstract Number: 3764

First author: Inder Bhamra

 

For further information, please contact:

 

Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Executive Chairman

 



Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc                                                          

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKMGMFVDMGRZM

Companies

Redx Pharma (REDX)
UK 100

Latest directors dealings